Anzeige
Mehr »
Login
Sonntag, 06.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Achtung Vervielfachung! URAN-AKTIEN starten durch …. Jetzt kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
240 Leser
Artikel bewerten:
(1)

Specialty Enzymes Market worth $9.2 billion by 2029 - Exclusive Report by MarketsandMarkets

CHICAGO, July 3, 2024 /PRNewswire/ -- The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarkets. The biopharmaceutical industry's rapid expansion, fueled by innovations in biotechnology and personalized medicine, offers significant growth opportunities for the specialty enzymes market. Enzymes are crucial in various biopharmaceutical manufacturing stages, such as protein expression, purification, and modification. They play a vital role in developing biologics, including monoclonal antibodies, vaccines, and gene therapies. With an aging population and a rising incidence of chronic diseases, the demand for biopharmaceuticals is increasing, consequently driving the need for enzymes in biopharmaceutical production.

MarketsandMarkets Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21682828

Browse in-depth TOC on "Specialty Enzymes Market"

297 - Tables
70 - Figures
306 - Pages

Advancements in enzyme engineering have enabled the discovery of new enzymes from natural sources, ensuring their safety and efficacy in various applications. This includes their use in producing specialty pharmaceuticals and in biocatalytic processes. A recent study by the University of Notre Dame researchers in January 2022 emphasized biocatalytic depolymerization as an efficient and sustainable method for plastic treatment, addressing environmental concerns and enhancing recycling efforts. Additionally, the Manchester Institute of Biotechnology (MIB) has developed an enzyme engineering platform to improve plastic degradation using directed evolution techniques. These advancements in genetic engineering and enzyme engineering for sustainable practices highlight the specialty enzymes market's growth potential, especially in addressing environmental issues and promoting eco-friendly solutions.

Protease segment is identified to be the fastest growing among the various types of enzymes during the forecast period.

Proteases' rapid growth is crucial in the pharmaceutical industry, where they are used in drug formulation and development. Proteases facilitate the synthesis of therapeutic proteins and peptides, which are essential for treating diseases like cancer, diabetes, and autoimmune disorders. Additionally, proteases are widely utilized in the biotechnology sector for protein engineering and modification. They enable precise cleavage and modification of proteins, which is fundamental in developing novel biopharmaceuticals and conducting advanced research. The increasing investment in biotechnology research and development significantly contributes to the growing demand for proteases. For example, the use of proteases in the production of insulin, a critical drug for diabetes management, showcases their importance. Companies like Novo Nordisk leverage proteases to enhance the efficiency and yield of insulin production, ensuring a reliable supply to meet the rising global demand.

Enzymes sourced from animals hold a significant share in the specialty enzymes market

Animal-derived enzymes are often preferred for their high specificity and efficiency in catalyzing biochemical reactions, which is essential in various specialized processes. Pancreatic enzymes, such as trypsin and chymotrypsin, are extensively used in drug formulation and the production of biologics. These enzymes help in the precise cleavage of peptide bonds, which is crucial for the development and manufacturing of therapeutic proteins and peptides. The specificity and activity levels of these enzymes make them indispensable in pharmaceutical applications, contributing significantly to their market share.

Additionally, animal-derived enzymes are essential in clinical diagnostics. Enzymes like rennet, obtained from the stomachs of calves, are used in the coagulation process in cheese production, showcasing their importance in the food industry. However, in clinical settings, enzymes like lactase, derived from animal sources, are used in diagnostic kits to test for lactose intolerance. This demonstrates their versatility and utility in both food processing and medical diagnostics. The significance of animal-sourced enzymes is the use of thrombin, derived from bovine sources, in surgical procedures. Thrombin is crucial for promoting blood clotting and is used in topical hemostatic agents to control bleeding during surgeries. The high efficacy and reliability of thrombin in medical applications underscore the importance of animal-derived enzymes in the specialty enzymes market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=21682828

North America region to dominate the specialty enzymes market during the forecast period.

North America holds the highest market share in the specialty enzymes market due to several key factors. The region is home to a robust pharmaceutical and biotechnology industry, characterized by significant investments in research and development. This investment landscape fosters innovation, leading to the development of advanced enzyme-based solutions. For instance, companies like Codexis, Inc. (US), are at the forefront of enzyme engineering, continuously developing new enzymes for pharmaceutical and industrial applications.

Moreover, the presence of well-established healthcare infrastructure and a high demand for diagnostic tools contribute to the market's growth. Specialty enzymes are crucial in various diagnostic applications, including ELISA (Enzyme-Linked Immunosorbent Assay) tests, which are widely used in medical diagnostics. The increasing prevalence of chronic diseases such as cancer and diabetes in North America drives the demand for these advanced diagnostic tools, further propelling the specialty enzymes market.

In addition, North America benefits from favorable regulatory frameworks that support the biotechnology sector. Agencies like the FDA (Food and Drug Administration) ensure the safety and efficacy of enzyme-based products, facilitating their adoption in medical and industrial applications.

Key players in this market include BRAIN Biotech AG (Germany), Novozymes A/S (Denmark), Codexis, Inc. (US), Sanofi (France), Merck KGaA (Germany), Dyadic International Inc (US), Advanced Enzyme Technologies (India), Amano Enzyme Inc (Japan), F. Hoffmann-La Roche Ltd (Switzerland), New England Biolabs (US), BBI Solutions (UK), Creative Enzymes (US), Bioseutica (Netherland), and SEKISUI Diagnostics (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=21682828

Browse Adjacent Reports @ Food and Beverage Market Research Reports & Consulting

Related Reports:

Industrial Enzymes Market by Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases), Application (Food & Beverages, Bioethanol, Feed, Detergents, Wastewater, Soil, and Oil Treatment), Source, Formulation and Region - Global Forecast to 2028

Food Enzymes Market by Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases), Source, Application (Food & Beverages), Formulation, and Region (North America, Europe, Asia Pacific, and South America) - Global Forecast to 2026

Feed Enzymes Market by Type (Phytase, Carbohydrase, and Protease), Livestock (Poultry, Swine, Ruminants, and Aquatic Animals), Source (Microorganism, Plant, and Animal), Form (Dry and Liquid), and Region - Global Forecast to 2025

About MarketsandMarkets

MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/specialty-enzymes-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/specialty-enzymes.asp

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/specialty-enzymes-market-worth-9-2-billion-by-2029--exclusive-report-by-marketsandmarkets-302188702.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.